|
Session 104
Poster Abstracts
NRTI Resistance: New Drugs, Mutations, Mechanisms, and In Vitro Dynamics
Monday, 1 - 4 pm
Poster Hall |
581
 |
Investigation of the Resistance Profile of Apricitabine in vitro
Fernado Frankel*1, H Xu1, J Coates2, and M Wainberg1
1McGill AIDS Ctr, Montreal, Canada and 2Avexa, Richmond, Victoria, Australia |
582
|
The Fitness and Antiviral Susceptibility of Unique HIV-RT Resistance Mutations of a Novel Thymidine Analog
Elijah Paintsil*1, G Dutschman1, S Grill1, M Baba2, H Tanaka3, G Yang1, and Y C Cheng1
1Yale Univ, New Haven, CT, US; 2Univ Sch of Med, Kagoshima, Japan; and 3Sch of Pharma Sci, Tokyo, Japan |
583
|
Susceptibility to 3TC Is Partially Maintained in Primary Human Macrophages despite the M184V Mutation
D Perez-Bercoff1, S Wurtzer1, S Compain2, H Benech2, and Francois Clavel*1
1INSERM U552, Hosp Bichat-Claude Bernard, Paris, France and 2CEA, Gif sur Yvette, France |
| 584 |
National Survey of Prevalence and Conditions of Selection of HIV-1 RT K70E Mutation
Constance Delaugerre*1, P Flandre2, A G Marcelin3, C Tamalet4, S Yerly5, D Descamps6, J Cottalorda7, V Schneider8, D Costagliola2, V Calvez3, and ANRS AC Resistance group
1Ambroise Pare Hosp, Boulogne, France; 2INSERM U720, Hosp Pitie-Salpetriere, Paris, France; 3Hosp Pitie-Salpetriere, Paris, France; 4Hosp La Timone, Marseille, France; 5Geneva Univ Hosp, Switzerland; 6Hosp Bichat, Paris, France; 7Hosp, Nice, France; and 8Hosp Tenon, Paris, France |
585
|
Molecular Characterization of Subtype C HIV-1 Reverse Transcriptase Harboring K65R and K65R/M184V Mutations
Dimitrios Coutsinos*, H Xu, M Ntemgwa, F Frankel, D Turner, B Spira, M Wainberg, and B Brenner
McGill AIDS Ctr, Lady Davis Inst, Jewish Gen Hosp, Montreal, Canada |
586
|
The A62V Mutation in HIV-1 Reverse Transcriptase Increases the Inhibitory Effects of the PPi Analog Foscarnet
Brian Scarth* and M Gotte
McGill Univ, Montreal, Canada |
587
|
Dynamics of NRTI-resistance Mutations during Treatment Interruption after Failure of NRTI-containing Regimens
Francesca Ceccherini-Silberstein*1, V Svicher1, M Zaccarelli2, M Santoro1, M Trignetti1, E Boumis2, P De Longis2, P Narciso2, A Antinori2, and C F Perno1
1Univ of Tor Vergata, Rome, Italy and 2Natl Inst of Infectious Diseases, L Spallanzani, Rome, Italy |
588
|
Continued Evolution of pol after Interruption of RTI in Patients with Advanced HIV Disease
Roger Paredes*1,2, Roger Paredes*1,2, M Sagar1, R Hoh3, J Martin3, N Parkin4, C Petropoulos4, S Deeks3, and D Kuritzkes1
1Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US; 2Fndn irsiCaixa, Hosp Univ Germans Trias i Pujol, Badalona, Catalonia, Spain; 3Univ of California, San Francisco and San Francisco Gen Hosp, US; and 4Monogram Biosci, South San Francisco, CA, US |
589
|
HIV-2 Reverse Transcriptase Resistance Mutations Are Present in PBMC DNA in ART-treated Subjects with Low Plasma Viral Loads
Geoffrey Gottlieb*1, C Ndour2, S Hawes1, A Starling1, K Wong1, S Dye1, R Smith1, N Kiviat1, J Mullins1, and P Sow2
1Univ of Washington, Seattle, US and 2Univ Cheikh Anta Diop, Dakar, Senegal |
590
|
Characterization of HIV-1 Variants Resistant to Heterocyclic Compounds that Inhibit Rev-RRE Function
Deidra Shuck-Lee*1, R Ptak2, M L Hammarskjold1, and D Rekosh1
1Myles H Thaler Ctr for AIDS Res, Univ of Virginia, Charlottesville, US and 2Southern Res Inst, Frederick, MD, US |
|
